CD8A and neoplasm: Further advancements include anti-TGF-β/PD-L1 bispecific antibodies, which effectively depleted Tregs and enhanced CD8+ T cell infiltration in non-inflamed tumors, resulting in substantial tumor growth inhibition [50].